Pular para o conteúdo principal
Ranking Invest

GOSS - Gossamer Bio, Inc.

Segmento: HealthcareGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Análise Ranking Invest

Valuation estimado
-23,57%
-$ 592.41 Mi
Valor de Mercado
$ 64.89 Mi
Desconto (AV)-111.0%
IVR
-9.13A companhia vale -9,13 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-7.74O valuation alternativo equivale a -774% do valor de mercado da companhia.
MLL
-7.74O lucro líquido dos controladores em 16 trimestres equivale a -774% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

-$ 94.03 Mi

Dívida Líquida

-$ 41.15 Mi

L4T

-$ 125.22 Mi

MM4T

-199.33%

Indicadores Básicos

ROE

133.17%

Índices de Previsibilidade

Receita Líquida

F0.55

Lucro

C0.32

Margem

D1.03

Índices de Tendência

Receita Líquida

A11.19

Lucro

B7.30

Margem

E-3.53

Índices de Endividamento

DIV/PAT

0.44

DIV/L4T

0.33

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.